+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Responses of normal and sickle cell hemoglobin to S-nitroscysteine: Implications for therapeutic applications of NO in treatment of sickle cell disease

Responses of normal and sickle cell hemoglobin to S-nitroscysteine: Implications for therapeutic applications of NO in treatment of sickle cell disease

Biophysical Chemistry 98(1-2): 165-181, 10 July

Factors which govern transnitrosation reactions between hemoglobin (Hb) and low molecular weight thiols may define the extent to which S-nitrosated Hb (SNO-Hb) plays a role in NO in the control of blood pressure and other NO-dependent reactions. We show that exposure to S-nitrosylated cysteine (CysNO) produces equivalent levels of SNO-Hb for Hb A(0) and sickle cell Hb (Hb S), although these proteins differ significantly in the electron affinity of their heme groups as measured by their anaerobic redox potentials. Dolphin Hb, a cooperative Hb with a redox potential like that of Hb S, produces less SNO-Hb, indicating that steric considerations outweigh effects of altered electron affinity at the active-site heme groups in control of SNO-Hb formation. Examination of oxygen binding at 5-20 mM heme concentrations revealed increases due to S-nitrosation in the apparent oxygen affinity of both Hb A(0) and Hb S, similar to increases seen at lower heme concentrations. As observed at lower heme levels, deoxygenation is not sufficient to trigger release of NO from SNO-Hb. A sharp increase in apparent oxygen affinity occurs for unmodified Hb S at concentrations above 12.5 mM, its minimum gelling concentration. This affinity increase still occurs in 30 and 60% S-nitrosated samples, but at higher heme concentration. This oxygen binding behavior is accompanied by decreased gel formation of the deoxygenated protein. S-nitrosation is thus shown to have an effect similar to that reported for other SH-group modifications of Hb S, in which R-state stabilization opposes Hb S aggregation.

(PDF emailed within 0-6 h: $19.90)

Accession: 011293834

Download citation: RISBibTeXText

PMID: 12128197

DOI: 10.1016/s0301-4622(02)00092-3

Related references

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine 90(6): 372-378, 2012

Normal vitamin e status in homozygous sickle cell anemia and hemoglobin sickle cell disease. Clinical Research 34(1): 137A, 1986

The distinct pathobiology of sickle cell-hemoglobin C disease. Therapeutic implications. Hematology/Oncology Clinics of North America 5(3): 433-451, 1991

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood 84(9): 3182-3188, 1994

The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Review of Hematology 10(12): 1087-1094, 2017

Screening of New Therapeutic Agents for the Treatment of Sickle Cell Disease Five-Year Summary of the NIH Sickle Cell Disease Reference Laboratory. Blood 100(11): Abstract No 3564, November 16, 2002

Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. New England Journal of Medicine 325(16): 1150-1154, 1991

Red cell life span in sickle cell-hemoglobin C disease with a note about sickle cell-hemoglobin O ARAB. Blood 45(2): 273-279, 1975

Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin. Pediatric Blood & Cancer: E27282-E27282, 2018

Hematological change in sickle cell hemoglobin c disease and in sickle cell beta thalassemia a cohort study from birth. British Journal of Haematology 60(2): 279-292, 1985

Outcome of pregnancy in sickle cell anemia and sickle cell-hemoglobin C disease. An analysis of 181 pregnancies in 98 patients, and a review of the literature. American Journal of Obstetrics and Gynecology 138(3): 239-245, 1980

Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cell hemoglobin-C disease but not in sickle cell anemia. Clinical Hemorheology and Microcirculation 55(2): 205-212, 2014

Hemoglobin A2 levels in healthy persons, sickle cell disease, sickle cell trait, and beta-thalassemia by capillary isoelectric focusing. American Journal of Clinical Pathology 107(1): 88-91, 1997

Studies in sickle-cell anemia. V. Sickle-cell hemoglobin C disease; report of two cases in siblings with clinical and genetic observations and a brief review of the literature. A.M.A. American Journal of Diseases of Children 90(1): 35-42, 1955